Novo Nordisk

NVOleader

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($42.6B)

Statische Daten (Echtzeitfinanzen werden geladen…)

GLP-1 Diabetes (Ozempic, Rybelsus) (42%)

Obesity (Wegovy) (25%)

Insulin (20%)

Rare Disease & Other (13%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Ozempic (semaglutide injection)32%

GLP-1 receptor agonist for type 2 diabetes

Wegovy (semaglutide for obesity)25%

GLP-1 agonist approved for chronic weight management

Rybelsus (oral semaglutide)8%

First oral GLP-1 for type 2 diabetes

Insulin Portfolio (Tresiba, NovoRapid)20%

Long-acting and rapid-acting insulin products

Rare Blood Disorders8%

Hemophilia treatments (NovoSeven, Esperoct)

Lieferkettenbeziehungen

Wettbewerber

Eli Lilly and Company

GLP-1 / obesity drugs

Auswirkung: Primary competitor — GLP-1 duopoly

Pfizer Inc.

Obesity and metabolic drugs

Auswirkung: Pfizer developing oral GLP-1

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Lieferketten-Probleme

↑ 생산 확대Wegovy 생산 캐파 2배 증설 완료

2026-04

덴마크·미국·프랑스 3개 공장 증설 완료로 Wegovy 공급 부족 해소. 2026Q2부터 대기 처방 소화 본격화.

★ 기회Amycretin(GLP-1+GIP) 3상 진입 — 차세대 파이프라인

2026-03

주1회 경구 복합제 Amycretin 3상 진입. 체중감소 효과 Wegovy 대비 +5%p 기대, 2028년 허가 목표.

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Novo Nordisk.

Unternehmensinformationen

Hauptsitz

Bagsvaerd, Denmark

Gegründet

1923

Mitarbeiter

64,000+

Website

novonordisk.com

Kaskadenposition

Rolle in der Kaskade

first follower

Typische Verzögerung

0-1 trading days

Novo Nordisk and Lilly form a GLP-1 duopoly; positive class data lifts both, while competitive data creates relative winners and losers.

Vollständige Kaskade anzeigen

Sektorübersicht — 제약 / 바이오

Sektornachrichten